1.Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
Huma SAEED ; Luis Antonio DÍAZ ; Antonio GIL-GÓMEZ ; Jeremy BURTON ; Jasmohan S. BAJAJ ; Manuel ROMERO-GOMEZ ; Marco ARRESE ; Juan Pablo ARAB ; Mohammad Qasim KHAN
Clinical and Molecular Hepatology 2025;31(Suppl):S94-S111
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.
2.Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
Huma SAEED ; Luis Antonio DÍAZ ; Antonio GIL-GÓMEZ ; Jeremy BURTON ; Jasmohan S. BAJAJ ; Manuel ROMERO-GOMEZ ; Marco ARRESE ; Juan Pablo ARAB ; Mohammad Qasim KHAN
Clinical and Molecular Hepatology 2025;31(Suppl):S94-S111
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.
3.Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
Huma SAEED ; Luis Antonio DÍAZ ; Antonio GIL-GÓMEZ ; Jeremy BURTON ; Jasmohan S. BAJAJ ; Manuel ROMERO-GOMEZ ; Marco ARRESE ; Juan Pablo ARAB ; Mohammad Qasim KHAN
Clinical and Molecular Hepatology 2025;31(Suppl):S94-S111
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as obesity and type 2 diabetes mellitus. This spectrum of liver disease ranges from isolated steatosis to more severe forms such as steatohepatitis, fibrosis, and cirrhosis. Recent studies highlight the role of gut microbiota in MASLD pathogenesis, showing that dysbiosis significantly impacts metabolic health and the progression of liver disease. This review critically evaluates current microbiome-centered therapies in MASLD management, including prebiotics, probiotics, synbiotics, fecal microbiota transplantation, and emerging therapies such as engineered bacteria and bacteriophage therapy. We explore the scientific rationale, clinical evidence, and potential mechanisms by which these interventions influence MASLD. The gut-liver axis is crucial in MASLD, with notable changes in microbiome composition linked to disease progression. For instance, specific microbial profiles and reduced alpha diversity are associated with MASLD severity. Therapeutic strategies targeting the microbiome could modulate disease progression by improving gut permeability, reducing endotoxin-producing bacteria, and altering bile acid metabolism. Although promising, these therapies require further research to fully understand their mechanisms and optimize their efficacy. This review integrates findings from clinical trials and experimental studies, providing a comprehensive overview of microbiome-centered therapies’ potential in managing MASLD. Future research should focus on personalized strategies, utilizing microbiome features, blood metabolites, and customized dietary interventions to enhance the effectiveness of these therapies.
4.Immediate sphincter repair following fistulotomy for anal fistula: does it impact the healing rate and septic complications?
Maher A. ABBAS ; Anna T. TSAY ; Mohammad ABBASS
Annals of Coloproctology 2024;40(3):217-224
Purpose:
Fistulotomy is considered the most effective treatment for anal fistula; however, it carries a risk of incontinence. Sphincteroplasty in the setting of fistulotomy is not standard practice due to concerns regarding healing and potential infectious complications. We aimed to compare the outcomes of patients who underwent fistulotomy with primary sphincteroplasty to those who did not undergo repair.
Methods:
This was a retrospective review of consecutive patients who underwent fistulotomy for cryptoglandular anal fistula. All operations were performed by one colorectal surgeon. Sphincteroplasty was performed for patients perceived to be at higher risk for continence disturbance. The main outcome measures were the healing rate and postoperative septic complications.
Results:
In total, 152 patients were analyzed. Group A (fistulotomy with sphincteroplasty) consisted of 45 patients and group B (fistulotomy alone) included 107 patients. Both groups were similar in age (P=0.16) and sex (P=0.20). Group A had higher proportions of multiple fistulas (26.7% vs. 6.5%, P<0.01) and complex fistulas (mid to high transsphincteric, 37.8% vs. 10.3%; P<0.01) than group B. The median follow-up time was 8 weeks. The overall healing rate was similar in both groups (93.3% vs. 90.6%, P=0.76). No significant difference between the 2 groups was noted in septic complications (6.7% vs. 3.7%, P=0.42).
Conclusion
Fistulotomy with primary sphincter repair demonstrated a comparable healing rate to fistulotomy alone, without an increased risk of postoperative septic complications. Further prospective randomized studies are needed to confirm these findings and to explore the functional outcomes of patients who undergo sphincteroplasty.
5.Exploring the Potential of Rosemary Derived Compounds (Rosmarinic and Carnosic Acids) as Cancer Therapeutics: Current Knowledge and Future Perspectives
Fazila SIRAJUDEEN ; Lara J. Bou MALHAB ; Yasser BUSTANJI ; Moyad SHAHWAN ; Karem H. ALZOUBI ; Mohammad H. SEMREEN ; Jalal TANEERA ; Waseem EL-HUNEIDI ; Eman ABU-GHARBIEH
Biomolecules & Therapeutics 2024;32(1):38-55
Cancer is a global health challenge with high morbidity and mortality rates. However, conventional cancer treatment methods often have severe side effects and limited success rates. In the last decade, extensive research has been conducted to develop safe, and efficient alternative treatments that do not have the limitations of existing anticancer medicines. Plant-derived compounds have shown promise in cancer treatment for their anti-carcinogenic and anti-proliferative properties. Rosmarinic acid (RA) and carnosic acid (CA) are potent polyphenolic compounds found in rosemary (Rosmarinus officinalis) extract. They have been extensively studied for their biological properties, which include anti-diabetic, anti-inflammatory, antioxidant, and anticancer activities. In addition, RA and CA have demonstrated effective anti-proliferative properties against various cancers, making them promising targets for extensive research to develop candidate or leading compounds for cancer treatment. This review discusses and summarizes the anti-tumor effect of RA and CA against various cancers and highlights the involved biochemical and mechanistic pathways.
6.Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy
Bisan El DAKKAK ; Jalal TANEERA ; Waseem EL-HUNEIDI ; Eman ABU-GHARBIEH ; Rifat HAMOUDI ; Mohammad H. SEMREEN ; Nelson C. SOARES ; Eman Y. ABU-RISH ; Mahmoud Y. ALKAWAREEK ; Alaaldin M. ALKILANY ; Yasser BUSTANJI
Biomolecules & Therapeutics 2024;32(3):267-280
Apoptosis, programmed cell death pathway, is a vital physiological mechanism that ensures cellular homeostasis and overall cellular well-being. In the context of cancer, where evasion of apoptosis is a hallmark, the overexpression of anti-apoptotic proteins like Bcl2, Bcl-xL and Mcl-1 has been documented. Consequently, these proteins have emerged as promising targets for therapeutic interventions. The BCL-2 protein family is central to apoptosis and plays a significant importance in determining cellular fate serving as a critical determinant in this biological process. This review offers a comprehensive exploration of the BCL-2 protein family, emphasizing its dual nature. Specifically, certain members of this family promote cell survival (known as anti-apoptotic proteins), while others are involved in facilitating cell death (referred to as pro-apoptotic and BH3-only proteins). The potential of directly targeting these proteins is examined, particularly due to their involvement in conferring resistance to traditional cancer therapies.The effectiveness of such targeting strategies is also discussed, considering the tumor’s propensity for anti-apoptotic pathways.Furthermore, the review highlights emerging research on combination therapies, where BCL-2 inhibitors are used synergistically with other treatments to enhance therapeutic outcomes. By understanding and manipulating the BCL-2 family and its associated pathways, we open doors to innovative and more effective cancer treatments, offering hope for resistant and aggressive cases.
7.Effect of three common hot beverages on the force decay of orthodontic elastomeric chain within a 28-day period: An in vitro study
Maziar NOBAHARI ; Fatemeh SAFARI ; Allahyar GERAMY ; Tabassom HOOSHMAND ; Mohammad Javad KHARAZIFARD ; Sepideh ARAB
The Korean Journal of Orthodontics 2024;54(3):153-159
Objective:
This study aimed to assess the effects of commonly consumed hot drinks on the force decay of orthodontic elastomeric chains.
Methods:
This in vitro experimental study evaluated 375 pieces of elastomeric chains with six rings placed on a jig. Four rings were stretched by 23.5 mm corresponding to the approximate distance between the canine and the second premolar.Fifteen pieces served as reference samples at time zero, and 360 pieces were randomized into four groups: control, hot water, hot tea, and hot coffee. Each group was further divided into six subgroups (n = 15) according to the different exposure periods. The specimens in the experimental groups were exposed to the respective solutions at 65.5°C four times per day for 90 seconds at 5-second intervals. The control group was exposed to artificial saliva at 37°C. The force decay of the samples was measured at 1, 2, 7, 14, 21, and 28 days using a universal testing machine. Data were analyzed using repeated-measures analysis of variance.
Results:
Maximum force decay occurred on day 1 in all groups. The minimum force was recorded in the control group, followed by the tea, coffee, and hot water groups on day 1. At the other time points, the minimum force was observed in the tea group, followed by the control, coffee, and hot water groups.
Conclusions
Patients can consume hot drinks without concern about any adverse effect on force decay of the orthodontic elastomeric chains.
8.The Role of Forensic Engineering in the Diagnosis of Electrocution Fatalities: Two Case Reports
Mohammad ALQASSIM ; Raneem EWISS ; Hamdah Al ALI
Safety and Health at Work 2023;14(1):124-130
The increase in the number of fatal electric accidents over the years has escalated the demand for specialized forensic engineers to determine their relevant technical causes. Likewise, the complexities associated with identifying the causes of electrocution accidents have prompted the General Department of Forensic Science and Criminology at Dubai Police to adopt a new methodology to diagnose electrocution accidents, consisting of an approach that involves medico-legal examination, electrical diagnosis of the evidence, and trace evidence analysis. This paper will discuss the application of the adopted method in further detail by unfolding two case reports. The first report outlines a case in which a worker got electrocuted at a construction site while attempting to turn on a lamp. The second case report involves the death of a technician in a workshop after trying to disconnect a washing machine from its plug. The methodology was utilized during the investigation of both cases, which were attended by the appointed forensic engineers and showed promising results.
10.Metagenomic Analysis of the Gut Microbiome Reveals Enrichment of Menaquinones (Vitamin K2) Pathway in Diabetes Mellitus
Nihar Ranjan DASH ; Mohammad Tahseen AL BATAINEH
Diabetes & Metabolism Journal 2021;45(1):77-85
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease with a high prevalence worldwide, especially among overweight and obese populations. T2DM is multifactorial with several genetic and acquired risk factors that lead to insulin resistance. Mounting evidence indicates that alteration of gut microbiome composition contribute to insulin resistance and inflammation. However, the precise link between T2DM and gut microbiome role and composition remains unknown. We evaluated the metabolic capabilities of the gut microbiome of twelve T2DM and six healthy individuals through shotgun metagenomics using MiSeq platform. We identified no significant differences in the overall taxonomic composition between healthy and T2DM subjects when controlling for differences in diet. However, results showed that T2DM enriched in metabolic pathways involved in menaquinone (vitamin K2) superpathway biosynthesis (PWY-5838) as compared to healthy individuals. Covariance analysis between the bacterial genera and metabolic pathways displaying difference in abundance (analysis of variance The identified differences in metabolic capabilities provide important information that may eventually lead to the development of novel biomarkers and more effective management strategies to treat T2DM.

Result Analysis
Print
Save
E-mail